No Data
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why
Catalyst Watch: Eyes on Electric Vehicle Deliveries, Retail Data and Housing Reads
Atara Biotherapeutics Analyst Ratings
Rodman & Renshaw Initiates Coverage on Atara Biotherapeutics With Buy Rating, $25 Price Target
Kyverna Therapeutics Picks Former Atara Bio, Kite Executives for Leadership Roles
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive...
No Data
101674396 : I miss chance to bought at 12plus
152398576 OP 101674396 : I was holding, but sold to put elsewhere. Wanted to buy back at 13, so was waiting. I missed the chance
101674396 152398576 OP : Very less to drop.. the approval date was very near
152398576 OP 101674396 : unfortunate